Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Renub Research | PRODUCT CODE: 1671287

Cover Image

PUBLISHER: Renub Research | PRODUCT CODE: 1671287

Global Self-Monitoring Blood Glucose Device Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

PUBLISHED:
PAGES: 200 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 2990
PDF (5 User License + Excel)
USD 3490
PDF (Corporate License)
USD 3990

Add to Cart

Global Blood Glucose Device Market Size

Blood Glucose Device market is expected to reach US$ 22.45 billion by 2033 from US$ 12.41 billion in 2024, with a CAGR of 6.81% from 2025 to 2033. The rising incidence of diabetes worldwide, rising awareness of the importance of blood glucose monitoring, the aging population, supportive government programs and healthcare regulations, and notable technology developments are the main factors propelling the market.

Blood Glucose Device Market Global Report by Product (Test Strips, Lancets, Blood Glucose Meters), Application (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), End User (Hospital Pharmacies, Retail Pharmacies, Online Sales, Diabetes Clinics & Centers), Countries and Company Analysis 2025-2033

Blood Glucose Device Industry Overview

Due to the fact that millions of individuals are diagnosed with diabetes each year, the blood glucose gadget sector has grown significantly. Because managing diabetes necessitates regular blood glucose testing, there is an increasing need for effective, user-friendly, and precise glucose monitoring equipment. Technological developments that allow for real-time surveillance and improved diabetes management, such as wearable technologies, continuous glucose monitoring systems, and integration with mobile apps, are driving the market. Additionally, because older persons are more prone to have chronic illnesses like diabetes, the aging population-especially in industrialized countries-is helping to grow the clientele. Government programs and healthcare policies that enhance diabetes treatment and encourage preventive health are also essential for industry expansion.

As businesses concentrate on creating more precise, non-invasive, and reasonably priced glucose monitoring solutions, technological innovation continues to be a major industry driver. There is great potential for non-invasive technologies, including those that use optical sensors or sweat analysis, to lessen the pain and inconvenience connected with conventional fingerstick testing. Furthermore, the possibility for individualized treatment has increased due to developments in data analytics and cloud-based technologies, enabling both patients and healthcare professionals to make well-informed decisions. With these developments, the market for blood glucose devices is expected to grow further, meeting the demands of a world population that is becoming more health conscious and making diabetes treatment easier and more convenient.

The rising incidence of diabetes and the aging population's increased vulnerability to diseases like it are the main factors driving the market. Additionally, the launch of new products and growing awareness of diabetes prevention strategies are driving market expansion. A common and expanding worldwide issue, diabetes is typified by the pancreas' incapacity to effectively generate insulin, which raises blood glucose levels. About 537 million people were diagnosed with diabetes in 2021, and estimates suggest that number will increase to 643 million by 2030 and 783 million by 2045, according to the International Diabetes Federation.

Growth Drivers for the Blood Glucose Device Market

Predictive analysis and artificial intelligence

Large volumes of data, including lifestyle characteristics, medical records, and other sources, are gathered by AI-powered algorithms from glucose monitoring devices. Patients with diabetes and their healthcare practitioners can make well-informed decisions about controlling the condition thanks to these analytics forecasts that uncover patterns, glucose levels, and trends. Additionally, AI algorithms optimize insulin dosages, tailor treatment regimens, and suggest treatments, all of which improve health outcomes. As artificial intelligence (AI) develops, its incorporation into blood glucose monitoring devices is transforming the market and enabling patients to lead better lifestyles. For example, the health technology startup January AI has released a cutting-edge app that uses generative artificial intelligence (AI) to assess and forecast how people's blood sugar would react to over 32 million different foods.

The launch of wearable technology

One important technical trend in the market for blood glucose monitoring devices is the creation of wearable technology. These tools can provide a simple and non-invasive way to keep an eye on their blood sugar levels all day long. These wearable gadgets, which use sensors to detect the amount of glucose in bodily fluids or interstitial fluid, are made to be worn on the body as bands or wristbands. Because these devices provide real-time data, patients may monitor changes in their blood sugar levels and modify their food, lifestyle, and medicine. The Dexcom Stelo Glucose Biosensor device, an integrated continuous glucose monitoring device (iCGM), received FDA approval in March 2024. This over-the-counter (OTC) CGM continually measures, records, analyzes, and displays blood glucose levels using a wearable sensor and an app. The gadget is intended for those with problematic hypoglycemia (low blood sugar levels) who are at least 18 years of age and do not take insulin.

Growing Diabetes Prevalence

The market is being driven by the rising incidence of diabetes worldwide, which is caused by sedentary lifestyles and declining eating habits. The number of individuals with diabetes is expected to treble over the next three decades, reaching 1.3 billion by 2050, according to research from the global burden of disease published in the Lancet. For people with diabetes to effectively manage their condition, blood glucose levels must be regularly monitored. Additionally, the use of blood glucose monitoring devices is steadily growing as people become more conscious of the importance of preventative healthcare. In addition, governments and healthcare institutions worldwide are working to prevent and control diabetes through a variety of programs and policies.

Challenges in the Blood Glucose Device Market

Limited Insurance Coverage

In the market for blood glucose devices, limited insurance coverage is a major problem because many insurance plans only pay a portion of or nothing at all for glucose monitoring devices, especially cutting-edge models like continuous glucose monitors (CGMs). Access to necessary diabetes treatment tools is hampered by this lack of coverage, particularly for people with inadequate insurance policies or low incomes. Despite being more accurate and convenient than traditional fingerstick testing, CGMs are sometimes unaffordable without insurance help due to their high upfront cost. Patients might be compelled to use antiquated or ineffective monitoring techniques as a result, which would hinder their capacity to properly manage their disease and raise the total financial strain on the healthcare system.

Higher Market Competition

Intense manufacturer rivalry has resulted from increased market competitiveness in the blood glucose device sector, which may lead to price wars. Pricing becomes a crucial competitive tactic as additional businesses with comparable items enter the market. Consumers may find products more affordable as a result, while manufacturers frequently see a decline in profit margins. It may be difficult for little businesses, in particular, to compete on pricing with more established, bigger firms that can afford to cut costs. Price-cutting pressure can stifle creativity and limit businesses' capacity to spend money on R&D for emerging technologies. Furthermore, reduced profit margins could prompt cost-cutting initiatives that compromise customer service or product quality.

Blood Glucose Device Market Overview by Regions

By countries, the global Blood Glucose Device market is divided into United States, Canada, France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey, China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand, Brazil, Mexico, Argentina, South Africa, Saudi Arabia and UAE.

United States Blood Glucose Device Market

The market for blood glucose devices in the US is expanding significantly as a result of rising diabetes rates, technological developments, and growing recognition of the value of glucose monitoring. The requirement for reliable, real-time data to better manage diabetes has led to a sharp increase in demand for wearable technology, insulin pumps, and continuous glucose monitoring (CGM) systems. Market expansion is also supported by the aging population and the increased emphasis on preventative healthcare. Nevertheless, issues including exorbitant equipment expenses, restricted insurance coverage, and governmental barriers continue to exist. Notwithstanding these challenges, the U.S. market is anticipated to continue growing due to innovative non-invasive monitoring technologies, as well as supportive government programs and regulations aimed at enhancing diabetes care.

Diabetes tends to become more common as people age, and older folks are more likely to have the condition or experience its consequences. The pool of people at risk for diabetes grows as the senior population does, increasing the need for blood glucose monitoring equipment. For example, according to the National Diabetes Statistics Report, 27.2 million persons 65 and older in the United States had prediabetes in 2021. Research has demonstrated the efficacy and safety of real-time continuous glucose monitoring (CGM) for persons with type 2 diabetes who are 65 years of age or older.

United Kingdom Blood Glucose Device Market

Because diabetes is becoming more common, the market for blood glucose devices in the UK is growing, with a focus on early identification and improved disease management. Insulin pumps and continuous glucose monitoring (CGM) devices are becoming increasingly popular because they provide patients with more precise, real-time monitoring, which enhances diabetes care. Demand is also increased by the aging population and the increased emphasis on preventative healthcare. These devices are also becoming more widely available because to national diabetes programs and government-funded healthcare initiatives. Nevertheless, there are still issues that can prevent patients from accessing cutting-edge technology, such as exorbitant upfront expenses and uneven insurance coverage. Despite these obstacles, it is anticipated that continued technical developments and rising awareness would propel the UK market's expansion.

India Blood Glucose Device Market

The increasing prevalence of diabetes, which affects millions of people nationwide, is propelling the market for blood glucose devices in India. The demand for glucose monitoring devices, especially continuous glucose monitors (CGMs) and self-monitoring blood glucose (SMBG) devices, is rising due to the increased number of people with diabetes and growing awareness of the significance of blood glucose monitoring. Further driving market expansion are technological developments, such as the creation of reasonably priced, easily navigable gadgets. Nonetheless, issues including exorbitant equipment prices, restricted insurance coverage, and the requirement for upgrades to the healthcare infrastructure continue to exist. Notwithstanding these challenges, government programs aimed at enhancing diabetes care and rising healthcare expenditures are anticipated to propel the market for blood glucose devices in India's ongoing growth.

Saudi Arabia Blood Glucose Device Market

The increasing prevalence of diabetes, a significant health issue in the region, is driving growth in the Saudi Arabian market for blood glucose devices. The need for equipment like continuous glucose monitors and self-monitoring blood glucose (SMBG) devices is growing due to the large number of people with diabetes and the growing awareness of the need of blood glucose monitoring. The industry is expanding as a result of technological developments and the introduction of more accessible, user-friendly choices. The use of glucose monitoring devices is also being fueled by Saudi government healthcare programs, such as the promotion of diabetes care and preventive health measures. But issues like exorbitant prices and scant insurance coverage still exist. Notwithstanding these obstacles, the market is anticipated to keep expanding thanks to rising healthcare spending and better access to care.

Self-Monitoring Blood Glucose Device Market Segments

Product

1. Test Strips

2. Lancets

3. Blood Glucose Meters

Application

1. Type 1 Diabetes

2. Type 2 Diabetes

3. Gestational Diabetes

End User

1. Hospital Pharmacies

2. Retail Pharmacies

3. Online Sales

4. Diabetes Clinics & Centers

Countries

North America

  • United States
  • Canada

Europe

  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • Belgium
  • Netherlands
  • Turkey

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Thailand
  • Malaysia
  • Indonesia
  • New Zealand

Latin America

  • Brazil
  • Mexico
  • Argentina

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE

All the Key players have been covered from 5 Viewpoints:

  • Overview
  • Key Person
  • Product Analysis
  • Recent Development
  • Revenue

Key Players Analysis

1. Abbott Laboratories

2. Medtronic

3. Dexcom, Inc.

4. B. Braun Melsungen AG

5. DarioHealth Corp

6. Sanofi

7. Bionime Corporation

8. Novo Nordisk

Key Questions Answered in Report:

1. How big is the Blood Glucose Device industry?

The global Blood Glucose Device market size was valued at US$ 12.41 billion in 2024 and is expected to reach US$ 22.45 billion in 2033.

2. What is the Blood Glucose Device growth rate?

The global Blood Glucose Device market is expected to expand at a compound annual growth rate (CAGR) of 6.81% from 2025 to 2033.

3. Who are the key players in Blood Glucose Device industry?

Some key players operating in the Blood Glucose Device market includes Abbott Laboratories, Medtronic, Dexcom, Inc., B. Braun Melsungen AG, DarioHealth Corp, Sanofi, Bionime Corporation, Novo Nordisk.

4. What are the factors driving the Blood Glucose Device industry?

The blood glucose device market is being driven by a number of factors, including the expanding aging population, the need for continuous monitoring, individualized care, rising diabetes prevalence, technological improvements, and increased health awareness.

5. Which Region held the largest market share in the Blood Glucose Device industry?

North America is expected to hold the largest market share in the industry.

6. What segments are covered in the Blood Glucose Device Market report?

Products, Application, End User and Countries segment are covered in this report.

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. Global Self-Monitoring Blood Glucose Device Market

6. Global Self-Monitoring Blood Glucose Device Market Share Analysis

  • 6.1 By Products
  • 6.2 By Application
  • 6.3 By End User
  • 6.4 By Country

7. Product - Global Self-Monitoring Blood Glucose Device Market

  • 7.1 Test Strips
  • 7.2 Lancets
  • 7.3 Blood Glucose Meters

8. Application - Global Self-Monitoring Blood Glucose Device Market

  • 8.1 Type 1 Diabetes
  • 8.2 Type 2 Diabetes
  • 8.3 Gestational Diabetes

9. End User - Global Self-Monitoring Blood Glucose Device Market

  • 9.1 Hospital Pharmacies
  • 9.2 Retail Pharmacies
  • 9.3 Online Sales
  • 9.4 Diabetes Clinics & Centers

10. Countries - Global Self-Monitoring Blood Glucose Device Market

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
  • 10.2 Europe
    • 10.2.1 France
    • 10.2.2 Germany
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Belgium
    • 10.2.7 Netherlands
    • 10.2.8 Turkey
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 Australia
    • 10.3.5 South Korea
    • 10.3.6 Thailand
    • 10.3.7 Malaysia
    • 10.3.8 Indonesia
    • 10.3.9 New Zealand
  • 10.4 Latin America
    • 10.4.1 Brazil
    • 10.4.2 Mexico
    • 10.4.3 Argentina
  • 10.5 Middle East & Africa
    • 10.5.1 South Africa
    • 10.5.2 Saudi Arabia
    • 10.5.3 United Arab Emirates

11. Porter's Five Forces

  • 11.1 Bargaining Power of Buyer
  • 11.2 Bargaining Power of Supplier
  • 11.3 Threat of New Entrants
  • 11.4 Rivalry among Existing Competitors
  • 11.5 Threat of Substitute Products

12. SWOT Analysis

  • 12.1 Strengths
  • 12.2 Weaknesses
  • 12.3 Opportunities
  • 12.4 Threats

13. Reimbursement Policy

14. Company Analysis

  • 14.1 Abbott Laboratories
    • 14.1.1 Overviews
    • 14.1.2 Key Persons
    • 14.1.3 Product Analysis
    • 14.1.4 Recent Development
    • 14.1.5 Revenues
  • 14.2 Medtronic
    • 14.2.1 Overviews
    • 14.2.2 Key Persons
    • 14.2.3 Product Analysis
    • 14.2.4 Recent Development
    • 14.2.5 Revenues
  • 14.3 Dexcom, Inc.
    • 14.3.1 Overviews
    • 14.3.2 Key Persons
    • 14.3.3 Product Analysis
    • 14.3.4 Recent Development
    • 14.3.5 Revenues
  • 14.4 B. Braun Melsungen AG
    • 14.4.1 Overviews
    • 14.4.2 Key Persons
    • 14.4.3 Product Analysis
    • 14.4.4 Recent Development
    • 14.4.5 Revenues
  • 14.5 DarioHealth Corp
    • 14.5.1 Overviews
    • 14.5.2 Key Persons
    • 14.5.3 Product Analysis
    • 14.5.4 Recent Development
    • 14.5.5 Revenues
  • 14.6 Sanofi
    • 14.6.1 Overviews
    • 14.6.2 Key Persons
    • 14.6.3 Product Analysis
    • 14.6.4 Recent Development
    • 14.6.5 Revenues
  • 14.7 Bionime Corporation
    • 14.7.1 Overviews
    • 14.7.2 Recent Developments
    • 14.7.3 Revenues
  • 14.8 Novo Nordisk
    • 14.8.1 Overviews
    • 14.8.2 Key Persons
    • 14.8.3 Product Analysis
    • 14.8.4 Recent Development
    • 14.8.5 Revenues
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!